MARKET

RIGL

RIGL

Rigel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.270
+0.040
+1.79%
After Hours: 2.230 -0.04 -1.76% 19:53 09/25 EDT
OPEN
2.230
PREV CLOSE
2.230
HIGH
2.370
LOW
2.220
VOLUME
2.13M
TURNOVER
--
52 WEEK HIGH
5.24
52 WEEK LOW
1.230
MARKET CAP
383.47M
P/E (TTM)
-15.1941
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study
Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.
Zacks · 09/18 14:52
Return On Capital Employed Overview: Rigel Pharmaceuticals
Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 sales of $16.02 million. Earnings fell to a loss of $17.39 million, resulting in a 182.71% decrease from last quarter. In Q1, Rigel Pharmaceuticals earned $21.03 million, and total sales reached $55.76 million.Why ROCE Is Significant Return on Capital
Benzinga · 09/17 14:46
Rigel's stock jumps on start of Phase 2 trial for investigational COVID-19 treatment
Shares of Rigel Pharmaceuticals Inc. undefined were up 10.4% in premarket trading on Thursday after the company said it had started a randomized,...
MarketWatch · 09/17 12:53
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood
PR Newswire · 09/17 12:30
Rigel Pharma initiates fostamatinib mid-stage study for COVID-19
Rigel Pharmaceuticals (RIGL) rises 14% in premarket, in reaction to commencement of a Phase 2 trial of fostamatinib, its oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients.The study is sponsored
Seekingalpha · 09/17 11:52
Rigel Announces NIH/NHLBI-Sponsored Trial Of Fostamatinib In Hospitalized COVID-19 Patients In Collaboration With Inova
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral
Benzinga · 09/17 11:31
NIH launches trial of Rigel drug for severe COVID-19
The U.S. National Institutes of Health on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe COVID-19, the disease caused by the novel coronavirus. The tablets, sold under the brand name Tavalisse
Reuters · 09/17 11:30
Rigel to Present at Two Upcoming Investor Conferences
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in September.
PR Newswire · 09/09 11:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RIGL. Analyze the recent business situations of Rigel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RIGL stock price target is 7.33 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 184
Institutional Holdings: 158.69M
% Owned: 93.94%
Shares Outstanding: 168.93M
TypeInstitutionsShares
Increased
52
11.37M
New
26
2.23M
Decreased
33
18.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Director
Raul Rodriguez
Chief Financial Officer/Executive Vice President
Dean Schorno
Executive Vice President/General Counsel/Secretary
Dolly Vance
Executive Vice President
Wolfgang Dummer
Executive Vice President
David Santos
Senior Vice President
Esteban Masuda
Independent Director
Bradford Goodwin
Independent Director
Keith Katkin
Independent Director
Brian Kotzin
Independent Director
Gregg Lapointe
Independent Director
Gary Lyons
Independent Director
Walter Moos
Independent Director
Jane Wasman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RIGL
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.